Skip to content

News · CDMO

Japan biosimilar CDMO: four firms sign share subscription

· Sources: 2 · Translated from the Japanese edition

Photo: CHUTTERSNAP / Unsplash

Alfresa Holdings, Mycenax Biotech of Taiwan (MBI), Kidswell Bio and Chiome Bioscience said on November 9, 2026 that they have signed an agreement to subscribe for shares in Alfenax Biologics. Alfenax was set up in January 2026 as a wholly owned subsidiary of Alfresa Holdings, under a shareholders agreement the four companies concluded in November 2025. Its business is biopharmaceutical contract development and manufacturing, plus distribution. Once payment is made, it is to become their joint venture.

Payment is set for November 25, and the split is 45, 45, 7 and 3

Payment is scheduled for November 25, 2026, and the companies put the capital after completion at ¥1,201 million. Alfresa Holdings and MBI will each hold 45%, Kidswell Bio 7% and Chiome Bioscience 3%.

The four describe the division of work this way. The Alfresa Group brings manufacturing and distribution, and MBI brings its knowledge of running a biopharmaceutical CDMO, with development and manufacturing know-how. Kidswell Bio brings biosimilar development and in-licensing, with four biosimilars already on the market, and Chiome brings antibody discovery and CMC development. MBI works from Taiwan and serves customers globally, with cell line construction, process and analytical method development, formulation work, commercial production and aseptic filling.

The plant goes inside an existing Alfresa site in Akita, and ground work is under way

The four will build the manufacturing site on the grounds of Alfresa Fine Chemical, a subsidiary of Alfresa Holdings, in Akita City in northern Japan. The four companies say ground preparation for construction is under way, and that the plan is to build integrated production there, from drug substance through drug product.

That pairing is the part worth watching. Drug substance means cell culture and purification; drug product means aseptic filling. The equipment and the skills differ, so whether both end up on one site, and on what timeline, is what a sponsor comparing contract manufacturers will want to pin down.

For a company supplying Japan from outside, a Japanese site moves where the paperwork sits. A site outside Japan needs Accreditation of Foreign Manufacturers for its buildings and facilities, the counterpart of the manufacturing licence a Japanese site holds. Japan's GMP Ministerial Ordinance applies either way, inside Japan or outside it.

Commercial production is targeted by the fiscal year ending March 2031

The companies are aiming to start commercial production by the fiscal year ending March 2031, and say the new company's business plan is still being worked out: which products, how much capacity, when the plant starts and at what scale. MHLW selected the project in May 2025 for its Support Program for the Establishment of Domestic Manufacturing Facilities for Biosimilars, the English name Alfresa uses for it.

The policy behind it is explicit. MHLW has set a target that by the end of fiscal 2029, the number of ingredients where biosimilars have taken 80% or more of the volume should reach 60% or more of all ingredients that have a biosimilar.

What to check if you are looking at this as a contract site

Most of what a sponsor needs is still open, so the questions are about timing. Ask when drug substance and drug product each come on line, what modality the site is being built for, what bioreactor scale and batch size it will run, and whether clinical supply will be taken alongside commercial products.

Technology transfer decides the lead time. The sponsor's own process may be brought in, or a process MBI runs in Taiwan may be moved to the Japanese site. Either way, the cell line, the culture and purification parameters and the analytical methods all have to be transferred and shown to be equivalent. Counting back from a commercial start, that work begins years earlier, and so does the capacity booking that goes with it.

The last item is the filing. Naming a manufacturing site in a marketing approval application brings a GMP compliance inspection, which the MAH applies for, and the schedule for construction, qualification and process validation then sits inside the filing schedule. For a biosimilar, where comparability to the reference product rests on a large analytical and clinical package, the site has to be settled early. The four signed the shareholders agreement for the venture on November 25, 2025.

Sources

  1. Share subscription agreement signed to make Alfenax Biologics a four-company joint venture (Japanese). Alfresa Holdings, via PR TIMES, Nov 2026.
  2. Policy for promoting the use of biosimilars (Japanese, PDF). MHLW, Sep 2024.

Read this story in Japanese